What the HHT?
A blog for the HHT community
CURE HHT OFFICIAL STATEMENT COVID-19 Traducción Española Update: April 2, 2020 Marie Faughnan, M.D., M.Sc – Director, Toronto HHT Centre of Excellence Director There is currently no research or evidence related to how people with hereditary hemorrhagic telangiectasia (HHT) experience COVID infection. In addition to the issues brought about by nosebleeds including increased touching of…Read More
On March 26, 2020, Sara Palmer, PhD, retired psychologist, Cure HHT President and author, along with Cure HHT Operations and Communications Manager Phyllis Loveland, addressed the stressors surrounding COVID-19, social distancing, isolation and the impact of “too much information”. Together, Dr. Palmer and Ms. Loveland provided reliable resources to lessen your fears, while keeping you informed,…Read More
A Message from Cure HHT Executive Director, Marianne Clancy To our HHT Community: Two years ago, we coined the phrase #InThisTogether as part of our annual year-end appeal. Now more than ever, this simple phrase has been on our minds and is driving all that we do during these unprecedented times surrounding the outbreak of the…Read More
The PATH Study is exploring the use of an oral medication called pomalidomide for the treatment of nosebleeds in HHT at 11 research centers across the United States. Find centers and check your eligibility. **Please note that recruitment may be impacted by health concerns over COVID-19. Please check with your local recruitment centers**Read More
Hyatt Regency – Bellevue, Washington **POSTPONED** Join us at our Patient & Physician conference in Washington for a unique education experience in the near future! This conference has been postponed from May 2020 due to health concerns related to COVID-19. Check back soon for updates on new dates and open registration.Read More